It was reported that the patient a large red area with black center and red rim spreading on the abdomen, which was the site of rituximab administration.The rituximab 1400mg was administered subcutaneously in the abdominal area using saf-t-intima iv catheter through syringe pump over 5 minutes.The pump was programmed used guardrails drug library.Due to the symptoms, the patient was admitted to the hospital for intravenous administration of antibiotics as well as infectious disease consult for possible cellulitis.The patient did not receive any additional rituximab, either intravenously or subcutaneously.Furthermore, it was mentioned that subcutaneous rituximab has been previously given through slow syringe administration.The facility recently changed their practice and began using syringe pumps.There were no reported incidents prior to use of pumps and after the event, the clinicians reverted to previous practice.
|